Investors with a keen eye to intrinsic value and opportunity should keenly focus their attention on this unique private placement.
The latest offering on the Stockhouse DealRoom is a pharmaceutical developer of R-107 – a non-gaseous, liquid prodrug of nitric oxide.
R-107 is a donor of nitric oxide, a gas that is naturally present in the lung and which improves blood flow in areas of the lungs that participate in gas exchange. The natural role of nitric oxide is to modulate pulmonary vascular resistance and pulmonary blood pressure, matching blood flow in the lung to areas rich in oxygen.
But, right now, it’s R-107’s importance in treating COVID-19 lung disease that makes the drug a potential game-changer.
Kalytera Therapeutics Inc. (
TSX-V.KALY,
OTCQB:KALTF,
Forum) is focused on and committed to positioning itself as a global leader in advancing new treatments for a variety of diseases and disorders by discovering, developing, manufacturing, and delivering innovative human therapeutics. Kalytera focuses on areas of unmet medical need and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people’s lives.
Kalytera announced on June 29, 2020 that it has entered into a binding Letter of Intent (LOI) to license R-107 from Salzman Group for treatment of coronavirus and COVID-19 infection. It will be an exclusive, worldwide license to develop and commercialize R-107 for coronavirus and COVID-19. Salzman Group is the inventor and owner of R-107 – a proprietary drug with the issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia, and South Korea.
R-107 is a non-gaseous, liquid prodrug of nitric oxide. Following a single administration by injection, R-107 slowly releases nitric oxide into lung tissues over 48 hours.
Increased Interest in Nitric Oxide for Treatment of Coronavirus and COVID-19 Infection
Within the past two months there has been an increased focus on the potential of nitric oxide for treatment of coronavirus and COVID-19 infection.
For example, Massachusetts General Hospital is initiating an international clinical study and will be the first hospital in the nation to rigorously test nitric oxide in coronavirus patients.
Dr. Lorenzo Berra, the critical-care specialist at Massachusetts General who is overseeing the new, international trial stated, “It’s a pretty remarkable drug. It has a risk profile that is minimal.” Dr. Keith Scott, principal investigator of the Louisiana component of the trial stated that, “We have tremendous confidence this therapy will alter the devastating effects of COVID-19, but we must test it. If results show promise, and since this gas is already FDA-approved, widespread use could begin immediately.”
Advantages of R-107 Over Nitric Oxide Gas
R-107 is a proprietary and novel molecule that acts as a nitric oxide donor. Nitric oxide normally exists in a gaseous state and is approved as such by the FDA for administration to patients via inhalation therapy requiring a special type of delivery device, and complex administration by trained respiratory therapists. R-107, in contrast, is a liquid that is readily administered by a single intramuscular injection.
Due to its ease of administration, R-107 will allow for thousands of patients to be treated simultaneously, in a potentially safe and less labor-intensive manner, without the need for special delivery equipment.
In contrast, nitric oxide gas must be administered via inhalation therapy through a CPAP breathing machine for 20 to 30 minutes twice a day. Administration is complex and labor-intensive, requiring a trained respiratory therapist, which substantially limits the number of patients that can be treated at any one time.
Respiratory viruses, such as SARS-CoV and COVID-19, can cause acute respiratory distress syndrome (ARDS), in which fluid leaks into the lungs, making breathing difficult or impossible. The prognosis with COVID-19 can be poor if the patient develops respiratory disease. R-107 will be developed for COVID-19 infection and, because there are no existing therapies or vaccines to effectively treat or prevent COVID-19, it is anticipated that the FDA will allow an expedited clinical development pathway for R-107 in this indication.
(Click image to enlarge)
Here’s the Deal:
Kalytera Therapeutics Inc. is currently offering shares to investors looking to enter the massive and booming pharmaceutical R&D market.
The Company is now marketing a CDN$450,000 private placement of up to 30,000,000 units at $0.015 per unit (that’s a
penny-and-a-half a share!) Kalytera’s stock is currently halted pending close of the private placement. The shares closed at $0.025 prior to the trading halt and will begin trading again upon completion of the private placement and execution of the License Agreement with Salzman Group that will give Kalytera exclusive, worldwide rights to R-107 for coronavirus and COVID-19 infection. Each unit comprises one (1) common share and as a bonus, also includes a one-half share purchase warrant.
For experienced retail investors, this deal equates to “ground floor” opportunity. It can also often translate into a real-world, high-value investment. Kalytera Therapeutics Inc. has already positioned itself as an established operator and major player in the cannabinoid (CBD) therapeutics sector and is reaching out to new investors who are looking for real value and opportunity in this exploding marketplace.
Kalytera Therapeutics’ DealRoom financing provides access to a company with a potentially game-changing drug, an experienced management team, and…at a very attractive valuation.
The
Stockhouse DealRoom: your destination to participate in exclusive financings, featuring some of the most innovative companies and best deals currently available on the market.
To sign up below and to receive materials related to participating in the current financing, click
here:
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a paid client ofStockhouse Publishing Ltd. (Stockhouse). Stockhouse is not registered as a broker, dealer, exempt market dealer, or any other registrant in any securities regulatory jurisdiction and will not be performing any registerable activity as defined by the applicable regulatory bodies. This deal room is for informational purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. Offers to sell, or the solicitations of offers to buy, any security can only be made through official offering documents that contain important information about risks, fees, and expenses. The information contained in this deal room is selective and does not purport to contain all the information relating to Kalytera Therapeutics Inc. In all cases, parties should conduct their own investigation and due diligence, not rely solely on the data provided herein and are encouraged to consult with a financial adviser, lawyer, accountant, and any other professional that can help to understand and assess the risks associated with any investment opportunity.